Exagamglogene autotemcel (Casgevy) gene therapy coverage
Customize your policy alerts
Sign up for meridian Policy MDN.CP.PHAR.603 alerts
Get alerted when Policy MDN.CP.PHAR.603 changes without checking for updates manually.
Monitor payer policy activity
Defines Meridian Health Plan medical necessity and authorization criteria for Casgevy (exagamglogene autotemcel) for patients with sickle cell disease or transfusion-dependent β-thalassemia, including required documentation and committee review. Affects providers submitting prior authorization for Medicaid line of business.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.